Picture loading failed.

Anti-MUC1 therapeutic antibody (Pre-made Gatipotuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes. Gatipotuzumab is being developed by Glycotope GMBH and is undergoing a phase II clinical trial for ovarian cancer.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-236-1mg 1mg 3090
GMP-Bios-ab-236-10mg 10mg 21890
GMP-Bios-ab-236-100mg 100mg 148000
GMP-Bios-ab-236-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MUC1 therapeutic antibody (Pre-made Gatipotuzumab biosimilar,Whole mAb)
INN Name Gatipotuzumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesNEMOD Biotherapeutics;Glycotope
Conditions Approvedna
Conditions ActiveOvarian cancer;Solid tumours;Fallopian tube cancer
Conditions Discontinuedna
Development TechGlycoExpress Technology